Expert Opin Investig Drugs. 2011 Nov;20(11):1471-7. doi: 10.1517/13543784.2011.619978. Epub 2011 Sep 21.
Insulin-like growth factor 1 receptor (IGF-1R) inhibitors have anti-tumor activity in various cancers. The development of IGF-1R inhibitors is a multi-dimensional and complex issue, involving many different drugs, and affecting several different points along the pathway. Matching patients with these agents based on molecular profiling/signatures will be essential for the proper development of this type of targeted agent.
胰岛素样生长因子 1 受体（IGF-1R）抑制剂在多种癌症中具有抗肿瘤活性。IGF-1R 抑制剂的开发是一个多维度且复杂的问题，涉及许多不同的药物，并影响该途径的多个不同靶点。根据分子谱/特征对这些药物进行匹配，对于这种靶向药物的正确开发至关重要。
